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receptor antagonist use at baselineDear Editor,
In Japan and the United States, leukotriene receptor antagonists
(LTRAs) are commonly prescribed for controlling asthma.1,2 The
Japanese guidelines for adult asthma recommend LTRAs for adult
patients with persistent asthma as an add-on controller option to
ICSs or a combination of ICS and LABAs.3 Moreover, the co-
administration of ICS and LTRAs creates an additional bronchodilat-
ing effect in asthma patients.4
Tiotropium, a long-acting muscarinic antagonist (LAMA), has
been newly included in the 2016 Global Initiative for Asthma
(GINA) guidelines as a bronchodilator treatment for asthma.5 In
phase 3 trials replicating the MezzoTinA trial, tiotropium had
similar efﬁcacy and tolerability to salmeterol when given as add-
on treatment tomedium-dose ICS, with or without LTRAs, in adults
with persistent asthma.6 Around 9% of patients in the MezzoTinAle 1
mographics and baseline patient characteristics.
LTRA use at baseline












ge, years 44.4 ± 12.8 43.2 ± 12.7 42.3 ± 12.7 42.
emale, n (%) 275 (58.3) 280 (59.4) 279 (56.5) 283
ace, n (%)
American Indian/Alaska Native 27 (5.7) 26 (5.5) 30 (6.1) 28
Asian 205 (43.4) 195 (41.4) 216 (43.7) 199
Black/African American 19 (4.0) 16 (3.4) 13 (2.6) 26
Hawaiian/Paciﬁc Islander 0 (0.0) 2 (0.4) 0 (0.0) 1 (
White 221 (46.8) 232 (49.3) 235 (47.6) 226
ody mass index, kg/m2 26.9 ± 6.1 26.6 ± 6.2 26.6 ± 6.2 27.
moking status, n (%)
Ex-smoker 87 (18.4) 71 (15.1) 77 (15.6) 66
Never smoked 385 (81.6) 400 (84.9) 417 (84.4) 414
moking history, pack-years 4.3 ± 2.8 4.0 ± 2.9 4.2 ± 2.7 4.0
uration of asthma, years 22.9 ± 15.1 22.0 ± 14.6 20.7 ± 14.0 20.
CS maintenance dose, mgz 663.1 ± 219.4 654.3 ± 216.8 646.4 ± 207.9 665
EV1, mL, at randomisation
(pre bronchodilation)
2203 ± 630 2269 ± 649 2327 ± 655 227
EV1,% predicted normal 74.1 ± 11.2 75.2 ± 11.5 75.7 ± 11.7 75.
CQ-7 score 2.2 ± 0.5 2.2 ± 0.5 2.2 ± 0.5 2.2
QLQ score 4.8 ± 1.0 4.8 ± 0.9 4.9 ± 0.9 4.9
ated set. All values are mean ± SD unless otherwise stated.
Q-7, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BID, tw
Placebo Respimat® once daily plus placebo hydroﬂuoroalkane metered-dose inhaler tw
Budesonide 400e800 mg or equivalent dose.
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1323-8930/Copyright © 2018, Japanese Society of Allergology. Production and hosting by Else
licenses/by-nc-nd/4.0/).trials were symptomatic at baseline despite treatment with
both ICS and LTRAs. Here, we examine whether LTRA use at base-
line impacts the efﬁcacy of tiotropium as add-on treatment to
medium-dose ICS in a post hoc analysis of data from the Mezzo-
TinA trials.
Detailed methods have been reported previously.6 Brieﬂy,
eligible patients were between 18 and 75 years of age, with symp-
tomatic asthma (mean Asthma Control Questionnaire [ACQ-7] score
of 1.5), a pre-bronchodilator FEV1 60e90% of predicted normal,
were under treatment withmedium-dose ICS (400e800 mg budeso-
nide or equivalent) and had never smoked or had a smoking history
of <10 pack-years, with no smoking 1 year before enrolment. Pa-
tients with COPD or who used concomitant LAMAs or LABAs within
4 weeks prior to randomisation were excluded. Patients could
continue use of LTRAs if taking them within 3 months before














4 ± 12.9 43.6 ± 11.0 44.9 ± 14.1 40.3 ± 14.4 47.0 ± 13.4
(59.0) 25 (55.6) 36 (75.0) 33 (70.2) 28 (65.1)
(5.8) 3 (6.7) 1 (2.1) 1 (2.1) 2 (4.7)
(41.5) 20 (44.4) 25 (52.1) 13 (27.7) 20 (46.5)
(5.4) 3 (6.7) 1 (2.1) 2 (4.3) 1 (2.3)
0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
(47.1) 19 (42.2) 21 (43.8) 31 (66.0) 20 (46.5)
0 ± 6.3 29.0 ± 7.8 26.7 ± 5.6 27.6 ± 6.8 26.7 ± 5.8
(13.8) 10 (22.2) 11 (22.9) 18 (38.3) 4 (9.3)
(86.3) 35 (77.8) 37 (77.1) 29 (61.7) 39 (90.7)
± 2.4 6.3 ± 4.6 3.8 ± 2.8 3.5 ± 2.8 6.1 ± 3.9
8 ± 13.5 24.0 ± 14.2 22.3 ± 10.9 23.2 ± 17.0 24.5 ± 14.8
.9 ± 216.5 672.0 ± 177.6 671.7 ± 175.2 696.2 ± 170.0 695.8 ± 227.3
5 ± 666 2224 ± 635 2227 ± 670 2429 ± 678 2083 ± 706
2 ± 11.4 72.3 ± 12.3 77.4 ± 11.7 77.5 ± 11.0 73.1 ± 12.6
± 0.5 2.2 ± 0.5 2.2 ± 0.5 2.2 ± 0.4 2.2 ± 0.5
± 0.9 4.8 ± 1.0 4.8 ± 0.9 4.8 ± 0.9 4.7 ± 0.8
ice daily; LTRA, leukotriene receptor antagonist; QD, once daily.
ice daily.
vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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mised (1:1:1:1) to self-administer once-daily tiotropium 5 mg via
Respimat® inhaler; once-daily tiotropium 2.5 mg (same device);
twice-daily salmeterol 50 mg via hydroﬂuoroalkane metered-dose
inhaler (HFA-MDI); or placebo (double-dummy design). The study
drug was administered as an add-on to maintenance treatment
with ICS (400e800 mg budesonide or equivalent). Rescue treatment
(salbutamol HFA-MDI) was permitted throughout the study. For
acute asthma exacerbations, temporary ICS dose increases and
temporary addition of systemic corticosteroids or theophylline
preparations were allowed.
Spirometric lung function tests were conducted to determine
peak and trough FEV1 values at randomisation and throughout
the treatment period. Peak FEV1 response, measured within 3 h af-
ter dosing (FEV1(0e3 h)), and trough FEV1 response, measured at the
end of the dosing interval (24 h after previous dose and 10 min
before next dose), at the end of the 24-week treatment period
were stratiﬁed by baseline LTRA use (yes/no).Fig. 1. Differences in lung function at week 24 by LTRA use at baseline compared with place
visit, baseline, treatment-by-visit and baseline-by-visit. The interaction term ‘treatment-by-s
ment effect across the subgroups. Common baseline mean ± SD ¼ 2265 ± 653 mL. Subgroup
overall, n ¼ 492; LTRA use at baseline: No, n ¼ 454; LTRA use at baseline: Yes, n ¼ 38. yPlace
within 3 h of dosing; LTRA, leukotriene receptor antagonist.Patients participated from 233 sites in 14 countries (Latvia,
Poland, Romania, Russia, Brazil, China, Colombia, Germany,
Guatemala, India, Japan, Mexico, Peru, and the United States). Of
2100 randomised patients (Japanese, 240), 183 were using an
LTRA at baseline (of these, tiotropium 5 mg was administered to
45 patients; tiotropium 2.5 mg, 48; salmeterol 50 mg, 47; placebo,
43). Overall, 1975 patients completed the study. Demographics
and baseline patient characteristics were comparable regardless
of LTRA use at baseline (Table 1). While only a slightly higher pro-
portion of Japanese patients with asthma had comorbid allergic
rhinitis compared to the overall population (81/240 [33.8%] vs.
608/2100 [29.0%], respectively), the proportion of Japanese patients
taking LTRAs was 3-fold higher than the overall population (60/240
[25.0%] vs. 183/2100 [8.7%], respectively).
Peak FEV1(0e3 h) and trough FEV1 improvements were indepen-
dent of LTRA use at baseline (interaction p values ¼ 0.9057 and
0.9083, respectively) (Fig. 1). Compared with the placebo
group, adjusted mean differences for peak FEV1(0e3 h) increasedbo; (A) Peak FEV1(0e3 h), (B) Trough FEV1. Full analysis set adjusted for treatment, study,
ubgroup’ and the term ‘subgroup’ were added to the linear model to evaluate the treat-
baseline values: No ¼ 2267 mL; Yes ¼ 2244 mL. Number of patients receiving placeboy:
bo Respimat® once daily plus placebo HFA-MDI twice daily. FEV1(0e3 h), FEV1 measured
Letter to the Editor / Allergology International 67 (2018) 411e413 413signiﬁcantly in both patients taking an LTRA at baseline (p < 0.05)
and in patients not taking an LTRA at baseline (p < 0.0001). Adjusted
mean differences for trough FEV1 also increased; a signiﬁcant
(p < 0.0001) difference was observed among patients not taking
an LTRA at baseline, and a similar, though not signiﬁcant, difference
was seen in patients taking an LTRA, probably due to lower patient
numbers. It must be noted that <10% of the study population used
LTRAs at baseline.
As the proportion of Japanese patients taking an LTRA was 3-
fold higher than the overall population, we reported peak
FEV1(0e3 h) and trough FEV1 in both populations. We did not
observe any difference in the improvement of respiratory function
regardless of whether patients were Japanese or non-Japanese
(interaction p values; peak FEV1, p ¼ 0.7352 and trough FEV1,
p ¼ 0.5234; Supplementary Table 1). In addition, the proportion
of ACQ-7 responders was recorded in patients with and without
LTRA use at baseline. There were more ACQ-7 responders in the
tiotropium 5 mg (with LTRA, OR [95% CI], 2.48 [1.00, 6.18],
p ¼ 0.0834; without LTRA, 1.25 [0.96, 1.63], p ¼ 0.1062) and
2.5 mg (with LTRA, 1.38 [0.59, 3.22], p ¼ 0.5226; without LTRA,
1.32 [1.01, 1.72], p ¼ 0.0456) groups and the salmeterol group
(with LTRA, 1.68 [0.71, 3.97], p ¼ 0.3262; without LTRA, 1.44 [1.11,
1.87], p ¼ 0.0080) than in the placebo group, regardless of LTRA
use at baseline. It must be noted that the OR of ACQ-7 responders
between the active drug groups and the placebo group exceeded 1
regardless of LTRA use at baseline.
Different mechanisms of action between LTRAs and tiotropium
may explain these observations. While LTRAs block leukotriene
D4, which induces bronchoconstriction and inﬂammation associ-
ated with asthma,7 tiotropium binds to muscarinic M3 receptors,
blocking the effects of acetylcholine on airway smooth muscle
and providing 24-h bronchodilation as it slowly dissociates.8 Co-
administration of LTRAs and ICS confers complementary effects
on inﬂammatory markers9 and yields an augmented bronchodi-
lator effect.4 In addition to blocking M3 muscarinic receptors on
airway smooth muscle, tiotropium in combination with corticoste-
roids has synergistically modulated airway inﬂammation in an an-
imal model of chronic asthma.10 These ﬁndings suggest that both
LTRAs and tiotropium possess bronchodilator effects that are
distinct and might be additive.
In conclusion, once-daily tiotropium added to ICS improves lung
function in patients with moderate symptomatic asthma, indepen-
dent of LTRA use at baseline. Future clinical studies with larger pop-
ulations evaluating impact of LTRAs on other markers should be
considered.
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